Cuál es el precio por Infinity Pharmaceuticals, Inc. (INFI)

Precio por Infinity Pharmaceuticals, Inc. (INFI) es de$0.0039

Cuál es la capitalización de mercado por Infinity Pharmaceuticals, Inc. (INFI)

Capitalización de mercado por Infinity Pharmaceuticals, Inc. (INFI) es $235.97K

Ganancias de Infinity Pharmaceuticals, Inc. (INFI)

Infinity Pharmaceuticals, Inc., established in 1995 and based in Cambridge, Massachusetts, operates as a biopharmaceutical firm dedicated to creating innovative therapies for individuals battling cancer. A central component of its pipeline is IPI-549, an experimental immuno-oncology drug taken orally. This candidate, currently in clinical development, functions by blocking the phosphoinositide-3-kinase-gamma enzyme. IPI-549 is undergoing Phase 2 trials for metastatic triple negative breast cancer and urothelial cancer, and Phase 1/1b trials for various solid tumors. The company maintains several strategic partnerships: with Intellikine, Inc. for the discovery, development, and commercialization of PI3K delta and/or gamma isoform-targeting pharmaceuticals; with Verastem, Inc. for the research, development, commercialization, and production of duvelisib and related compounds; and with PellePharm, Inc. to advance and commercialize its hedgehog inhibitor program, IPI-926, which is also a clinical-stage investigational drug. Furthermore, Infinity Pharmaceuticals holds collaborative agreements with Arcus Biosciences, Inc., F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company.

Año	Ganancias	Cambiar
Not enough data for the provided dates.

Año

Ganancias

Cambiar

Not enough data for the provided dates.

Empresa	Ganancias	Diferencia de ganancias	País
Vertex Pharmaceuticals Incorporated VRTX.US	$5.27B	-	US
Argenx SE ARGX.US	$1.95B	-	NL
Lonza Group AG LONN.SW	-	-	CH
Samsung Biologics Co.,Ltd. 207940.KS	-	-	KR
UCB S.A. UCB.BR	$3.01B	-	BE

Empresa

Ganancias

Diferencia de ganancias

País